RJA
ACRS icon

Raymond James & Associates’s Aclaris Therapeutics ACRS Stock Holding History

Raymond James & Associates’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-20,995
Closed -$542K – 3422
2017
Q3 		$542K Sell
20,995
-65
-0.3% -$1.74K ﹤0.01% 2435
2017
Q2 		$571K Buy
+21,060
New +$573K ﹤0.01% 2336

Other funds holding ACRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Raymond James & Associates's ACRS Position: Q4 2017 in Review

Raymond James & Associates sold out of Aclaris Therapeutics (ACRS) in Q4 2017, closing a stake of 20,995 shares — an estimated $542K sold.

Raymond James & Associates first reported a position in ACRS in Q2 2017 and held it in 2 quarters. The position peaked at $571K in Q2 2017. 102 funds tracked by Wall St. Rank hold ACRS as of Q4 2017.

  • Raymond James & Associates reported no remaining Aclaris Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Raymond James & Associates sold 20,995 Aclaris Therapeutics shares in Q4 2017, an estimated $542K.
  • Raymond James & Associates first reported a position in Aclaris Therapeutics in Q2 2017 and held it in 2 quarters.
  • Raymond James & Associates's Aclaris Therapeutics position peaked at $571K in Q2 2017.
  • 102 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2017.

Based on Raymond James & Associates's 13F filing for Q4 2017, filed 14 Feb 2018.